Do analysts prefer CPIX or UG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CPIX or UG?

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than United-Guardian. MarketBeat recorded 4 mentions for Cumberland Pharmaceuticals and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat Cumberland Pharmaceuticals' score of 0.85 indicating that United-Guardian is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United-Guardian 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate UG or VANI?

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 167.86%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts clearly believe Vivani Medical is more favorable than United-Guardian. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Does the media prefer UG or VANI?

In the previous week, Vivani Medical had 5 more articles in the media than United-Guardian. MarketBeat recorded 7 mentions for Vivani Medical and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat Vivani Medical's score of 0.93 indicating that United-Guardian is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United-Guardian 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivani Medical 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRXP or UG?

In the previous week, NRx Pharmaceuticals had 8 more articles in the media than United-Guardian. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat NRx Pharmaceuticals' score of 0.16 indicating that United-Guardian is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral United-Guardian 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PLYX or UG?

In the previous week, Polaryx Therapeutics had 5 more articles in the media than United-Guardian. MarketBeat recorded 7 mentions for Polaryx Therapeutics and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat Polaryx Therapeutics' score of 1.04 indicating that United-Guardian is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polaryx Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United-Guardian 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer UG or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United-Guardian 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, UG or RFL?

United-Guardian has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio United-Guardian $10.55M 3.11 $2.11M $0.54 13.24 Rafael $920K 113.44 -$30.52M -$0.68 N/A

Is UG or RFL more profitable?

United-Guardian has a net margin of 22.01% compared to Rafael's net margin of -3,321.74%. United-Guardian's return on equity of 22.24% beat Rafael's return on equity. Company Net Margins Return on Equity Return on Assets United-Guardian 22.01% 22.24% 19.12% Rafael -3,321.74% -41.27% -35.32%

United-Guardian (UG) Competitors

$7.15 0.00 (0.00%)

Closing price 08/14/2026 03:58 PM Eastern

Extended Trading

$7.15 0.00 (0.00%)

As of 08/14/2026 04:10 PM Eastern

Compare

UG vs. CPIX, VANI, NRXP, PLYX, and RFL

Should you buy United-Guardian stock or one of its competitors? United-Guardian's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Vivani Medical (VANI), NRx Pharmaceuticals (NRXP), Polaryx Therapeutics (PLYX), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does United-Guardian compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than United-Guardian. MarketBeat recorded 4 mentions for Cumberland Pharmaceuticals and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat Cumberland Pharmaceuticals' score of 0.85 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United-Guardian	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.2% of United-Guardian shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 29.0% of United-Guardian shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cumberland Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, United-Guardian has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

United-Guardian has a net margin of 22.01% compared to Cumberland Pharmaceuticals' net margin of -34.40%. United-Guardian's return on equity of 22.24% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
United-Guardian	22.01%	22.24%	19.12%

United-Guardian has lower revenue, but higher earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.62	-$2.84M	-$0.71	N/A
United-Guardian	$10.55M	3.11	$2.11M	$0.54	13.24

Summary

United-Guardian beats Cumberland Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does United-Guardian compare to Vivani Medical?

United-Guardian (NASDAQ:UG) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

United-Guardian has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

United-Guardian has a net margin of 22.01% compared to Vivani Medical's net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United-Guardian	22.01%	22.24%	19.12%
Vivani Medical	N/A	-191.05%	-70.91%

In the previous week, Vivani Medical had 5 more articles in the media than United-Guardian. MarketBeat recorded 7 mentions for Vivani Medical and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat Vivani Medical's score of 0.93 indicating that United-Guardian is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United-Guardian	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivani Medical	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 29.0% of United-Guardian shares are held by insiders. Comparatively, 53.3% of Vivani Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

United-Guardian has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United-Guardian	$10.55M	3.11	$2.11M	$0.54	13.24
Vivani Medical	N/A	N/A	-$26.61M	-$0.35	N/A

Vivani Medical has a consensus price target of $3.75, suggesting a potential upside of 167.86%. Given Vivani Medical's stronger consensus rating and higher probable upside, analysts clearly believe Vivani Medical is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

United-Guardian beats Vivani Medical on 9 of the 15 factors compared between the two stocks.

How does United-Guardian compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

United-Guardian has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	96.32	-$28.62M	-$0.55	N/A
United-Guardian	$10.55M	3.11	$2.11M	$0.54	13.24

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.2% of United-Guardian shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 29.0% of United-Guardian shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

United-Guardian has a net margin of 22.01% compared to NRx Pharmaceuticals' net margin of -691.81%. United-Guardian's return on equity of 22.24% beat NRx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-89.03%
United-Guardian	22.01%	22.24%	19.12%

NRx Pharmaceuticals presently has a consensus price target of $34.50, suggesting a potential upside of 955.05%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe NRx Pharmaceuticals is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, NRx Pharmaceuticals had 8 more articles in the media than United-Guardian. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat NRx Pharmaceuticals' score of 0.16 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
United-Guardian	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NRx Pharmaceuticals has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market. Comparatively, United-Guardian has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Summary

United-Guardian beats NRx Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does United-Guardian compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and United-Guardian (NASDAQ:UG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Polaryx Therapeutics currently has a consensus target price of $7.67, indicating a potential upside of 194.87%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Polaryx Therapeutics is more favorable than United-Guardian.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

23.2% of United-Guardian shares are owned by institutional investors. 45.8% of Polaryx Therapeutics shares are owned by insiders. Comparatively, 29.0% of United-Guardian shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

United-Guardian has a net margin of 22.01% compared to Polaryx Therapeutics' net margin of 0.00%. United-Guardian's return on equity of 22.24% beat Polaryx Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
United-Guardian	22.01%	22.24%	19.12%

In the previous week, Polaryx Therapeutics had 5 more articles in the media than United-Guardian. MarketBeat recorded 7 mentions for Polaryx Therapeutics and 2 mentions for United-Guardian. United-Guardian's average media sentiment score of 1.21 beat Polaryx Therapeutics' score of 1.04 indicating that United-Guardian is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polaryx Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
United-Guardian	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United-Guardian has higher revenue and earnings than Polaryx Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.05	N/A
United-Guardian	$10.55M	3.11	$2.11M	$0.54	13.24

Summary

United-Guardian beats Polaryx Therapeutics on 9 of the 15 factors compared between the two stocks.

How does United-Guardian compare to Rafael?

United-Guardian (NASDAQ:UG) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, United-Guardian had 2 more articles in the media than Rafael. MarketBeat recorded 2 mentions for United-Guardian and 0 mentions for Rafael. United-Guardian's average media sentiment score of 1.21 beat Rafael's score of 0.00 indicating that United-Guardian is being referred to more favorably in the media.

Company	Overall Sentiment
United-Guardian	Positive
Rafael	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United-Guardian	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

United-Guardian has higher revenue and earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than United-Guardian, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United-Guardian	$10.55M	3.11	$2.11M	$0.54	13.24
Rafael	$920K	113.44	-$30.52M	-$0.68	N/A

United-Guardian has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Rafael has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

23.2% of United-Guardian shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 29.0% of United-Guardian shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

United-Guardian has a net margin of 22.01% compared to Rafael's net margin of -3,321.74%. United-Guardian's return on equity of 22.24% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United-Guardian	22.01%	22.24%	19.12%
Rafael	-3,321.74%	-41.27%	-35.32%

Summary

United-Guardian beats Rafael on 12 of the 14 factors compared between the two stocks.

Get United-Guardian News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UG vs. The Competition

Export

Metric	United-Guardian	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.82M	$11.75B	$6.99B	$13.04B
Dividend Yield	8.39%	2.69%	2.56%	10.42%
P/E Ratio	13.24	782.03	271.55	25.35
Price / Sales	3.11	750.35	603.66	99.98
Price / Cash	14.84	15.03	28.87	38.43
Price / Book	2.93	10.34	11.17	6.52
Net Income	$2.11M	$2.78B	$3.45B	$346.81M
7 Day Performance	-1.79%	0.80%	0.95%	1.26%
1 Month Performance	-5.30%	0.62%	2.30%	2.56%
1 Year Performance	-9.38%	145.55%	62.36%	20.83%

United-Guardian Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UG United-Guardian	2.2418 of 5 stars	$7.15 flat	N/A	-9.4%	$32.82M	$10.55M	13.24	20	Positive News
CPIX Cumberland Pharmaceuticals	0.6163 of 5 stars	$8.01 +3.0%	N/A	+148.9%	$119.71M	$44.52M	N/A	80
VANI Vivani Medical	3.6354 of 5 stars	$1.38 -1.8%	$3.75 +172.7%	+12.0%	$118.58M	N/A	N/A	20	Earnings Report Analyst Upgrade
NRXP NRx Pharmaceuticals	2.3408 of 5 stars	$3.07 +0.7%	$38.25 +1,145.9%	+13.1%	$111.01M	$1.23M	N/A	2	Earnings Report Analyst Downgrade
PLYX Polaryx Therapeutics	4.4863 of 5 stars	$2.19 -2.0%	$8.50 +289.0%	N/A	$108.91M	N/A	N/A	11	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UG) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United-Guardian (UG) Competitors

UG vs. CPIX, VANI, NRXP, PLYX, and RFL

How does United-Guardian compare to Cumberland Pharmaceuticals?

Summary

How does United-Guardian compare to Vivani Medical?

Summary

How does United-Guardian compare to NRx Pharmaceuticals?

Summary

How does United-Guardian compare to Polaryx Therapeutics?

Summary

How does United-Guardian compare to Rafael?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UG vs. The Competition

United-Guardian Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United-Guardian (UG) Competitors

UG vs. CPIX, VANI, NRXP, PLYX, and RFL

How does United-Guardian compare to Cumberland Pharmaceuticals?

Do analysts prefer CPIX or UG?

Does the media refer more to CPIX or UG?

Do insiders & institutionals believe in CPIX or UG?

Which has more volatility & risk, CPIX or UG?

Is CPIX or UG more profitable?

Which has stronger earnings & valuation, CPIX or UG?

Summary

How does United-Guardian compare to Vivani Medical?

Which has more volatility & risk, UG or VANI?

Is UG or VANI more profitable?

Does the media prefer UG or VANI?

Do institutionals and insiders have more ownership in UG or VANI?

Which has higher earnings & valuation, UG or VANI?

Do analysts rate UG or VANI?

Summary

How does United-Guardian compare to NRx Pharmaceuticals?

Which has higher valuation and earnings, NRXP or UG?

Do institutionals & insiders have more ownership in NRXP or UG?

Is NRXP or UG more profitable?

Do analysts prefer NRXP or UG?

Does the media prefer NRXP or UG?

Which has more risk & volatility, NRXP or UG?

Summary

How does United-Guardian compare to Polaryx Therapeutics?

Do analysts recommend PLYX or UG?

Do insiders & institutionals have more ownership in PLYX or UG?

Is PLYX or UG more profitable?

Does the media refer more to PLYX or UG?

Which has preferable valuation & earnings, PLYX or UG?

Summary

How does United-Guardian compare to Rafael?

Does the media prefer UG or RFL?

Do analysts prefer UG or RFL?

Which has better valuation & earnings, UG or RFL?

Which has more volatility and risk, UG or RFL?

Do insiders and institutionals have more ownership in UG or RFL?

Is UG or RFL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UG vs. The Competition

United-Guardian Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools